7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
Published 3 months ago • 255 plays • Length 4:44Download video MP4
Download video MP3
Similar videos
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
2:01
the evolution of bcl2 inhibition in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
2:46
a phase ii trial of pembrolizumab for richter's transformation of cll
-
5:15
the only meaningful treatment for mild cognitive impairment
-
13:47
latest news in myeloma: mrd, bites, and car t-cells
-
6:36
anthony mato: loxo-305 demonstrates efficacy in patients with cll/sll
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
2:05
results from the phase i sal-relax trial: venetoclax plus cytarabine and mitoxantrone in r/r aml
-
1:07
primary findings from the epcore cll-1 trial of epcoritamab in cll and rt
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab